Reported Earnings • May 14
Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025) Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. 공시 • Feb 05
Schott Pharma Ag & Co. Kgaa Approves Dividend SCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income. New Risk • Jan 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. 공시 • Dec 22
SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026 SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Dec 14
Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024) Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe. 공시 • Dec 12
SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026 SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. 공시 • Dec 06
SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025 SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025 공시 • Oct 09
SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026 SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026 공시 • Jun 13
SCHOTT Pharma Management AG Announces CFO Changes The Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden. 공시 • Nov 16
SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025 SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025